The case in front of me: a sterility test · dimerisation · tirzepatide.
I have used one of these for a while and I am considering switching, which requires a reason.
What I care about is reproducibility, because a result I cannot repeat is not useful to me.
What does each option buy me, and what does it cost me?
Answer first: peptide mapping is the test that earns its cost exactly when mass spectrometry on the intact molecule is uninformative, which is more often than people expect.
Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
On the detail: a D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.
Ask for the coverage figure with any map. Without it the result is not interpretable.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant limitation is that a mass-neutral substitution has the same molecular weight as the correct residue and can co-elute under a routine gradient.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
For a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
Trypsin cleaving C-terminal to lysine and arginine, except before proline, is the standard specificity and is what makes a theoretical digest predictable.
A missing expected fragment is as informative as an unexpected one.
Start with what you are trying to detect, because mapping answers a specific question — where in the sequence — rather than a general one.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
More usefully, cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
Peptide mapping is a compendial identity method for peptide and protein products and is specified in the relevant pharmacopoeial general chapters.
Non-reduced mapping is how you confirm disulfide pairings.
In practice, post-translational and chemical modifications show up as a mass shift on a specific fragment, which is exactly the information intact mass throws away.
Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Commission it on a first lot from a new supplier, not on every lot.
edited 19 Jan 2025 by Dr_Priya_Raghunathan — removed a claim I could not source
The short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.
The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.
Mapping is for mass-neutral problems. That is when it earns its cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.